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Abstract
The NEUrocognitive (NEU) Screen is a practical tool proposed to screen for HIV-associated cognitive impairment in the clinical
setting. This is a pencil-and-paper method that can be applied rapidly (#10 minutes for administration) and has no copyright
limitations. In this study, we aimed at investigating its diagnostic accuracy in an older population of persons living with HIV (PLWH),
with cutoffs set at 30, 40, 50, and 60 years. Data were collected from a sample of 368 PLWH who underwent a comprehensive
neuropsychological tests battery (gold standard). Results of statistical tests showed that accuracy of the NEUScreen increased with
ageof the participants. The highest degree of precision,with a sensitivity of 91%and specificity of 92%,wasobtained for people aged
60 years or older (correct classification: 91%). These optimal results point to the great potential of the NEU Screen as a tool for
detecting cognitive disorders in older PLWH.
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The cerebral manifestations of HIV infection remainan issue of concern in the everyday practice of HIV
medicine. Despite current widespread access to combi-
nation antiretroviral therapy, a large percentage of
chronically infected persons living with HIV (PLWH)
exhibitHIV-associated neurocognitive disorders (HAND;
Eggers et al., 2017). HIV-associated neurocognitive dis-
orders are linked to a poorer quality of life, worse daily
functioning, higher rates of unemployment, greater use of
health system resources, and diminished adherence to
combination antiretroviral therapy (Gorman, Foley,
Ettenhofer, Hinkin, & van Gorp, 2009). As a result, the
detection, prevention, and treatment of HAND have be-
come research priorities in the field of HIV.
To date, several different methods to screen for cog-
nitive impairment in PLWH have been proposed
(Kamminga, Cysique, Lu, Batchelor, & Brew, 2013;
Zipursky et al., 2013).One of themostwidely used is the
HIVDementia Scale (Power, Selnes,Grim,&McArthur,
1995) and its derivative form, the International HIV
Dementia Scale (Sacktor et al., 2005). However, several
studies have shown that although both instruments are
useful for detecting HIV-related dementia, they are less
sensitive for milder HAND (Bottiggi et al., 2007; Val-
cour, Paul, Chiao, Wendelken, & Miller, 2011). Other
studies have assessed the accuracy of the Montreal
Cognitive Assessment instrument (Nasreddine et al.,
2005), an easily accessible exploratory tool, in detecting
cognitive impairment associated with HIV. However,
although different cutoff points for the detection of
cognitive disruption by this tool have been proposed,
none of them yield rates for both sensitivity and speci-
ficity greater than70%(Fazeli et al., 2017;Hasbun et al.,
2012; Janssen, Bosch, Koopmans,&Kessels, 2015; Kim
et al., 2016; Milanini et al., 2016, 2014; Overton et al.,
2013). Finally, the Brief Neurocognitive Screen (Ellis
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et al., 2005), which includes the Trail Making Test
(TMT)PartsAandB (Reitan&Davidson, 1974) and the
Wechsler Adult Intelligence Scale (WAIS) III Digit
Symbol test (Wechsler, 1999), has been shown to achieve
a sensitivity of 65%and specificity of 72%.Nonetheless,
none of these tools appears to have gained widespread
acceptance in routine clinical practice. There are various
possible reasons for this, among them, the time required
for their administration, the lack of clinical studies as
opposed to merely research-based studies, and, above
all, the inadequate levels of diagnostic accuracy that
most of them have revealed (Valcour, 2011).
The NEUrocognitive (NEU) Screen is a method that
was developed to detect cognitive impairment in PLWH
in day-to-day clinical practice (Muñoz-Moreno et al.,
2013). For its development, we analyzed which combi-
nations of neuropsychological tests were most sensitive
and specific in the detection of cognitive disorders in
a sample of 114 people with HIV from different treat-
ment centers in Catalonia, Spain. The combinations
were decided upon taking into account that their ad-
ministration time had to be short (,10 minutes) and
simple (without needing anything other than paper
and pencil). The combination with the best sensitivity
and specificity (74%and81%, respectively)madeup the
NEU Screen.
Given that the population of PLWH is steadily aging,
there is a growing need to be able to obtain information
quickly and easily about not only the physical, but also
the mental status of older adults living with HIV.
However, at present, there is a significant lack of in-
formation about tools that can screen for cognitive im-
pairment in this population. To help fill that gap, in this
study, we investigated the accuracy of the NEU Screen
for an older HIV population at different stages of aging.
Methods
Study Population and Design
Weused clinical information from a voluntary sample of
368 PLWH receiving outpatient services at seven hos-
pitals in Barcelona, Catalonia, Spain. Demographic,
medical, and neurocognitive data were available for all
participants. They were all at least 18 years of age, had
confirmed HIV infection, and had undergone a compre-
hensive neuropsychological assessment. As themeasures
that make up the NEU Screen had been included in the
comprehensive evaluation, we were able to use the data
thus obtained to perform the present investigation. The
work was conducted in compliance with the Helsinki
Declaration of 1964 (1996 revision) and Good Clinical
Practice guidelines, and all participants providedwritten
informed consent. The information collected for data
analyses was obtained from January 2004 to December
2015.
Measures
The measures included in the comprehensive battery of
neuropsychological tests covered seven domains, com-
prising a total of 15 scores. The specific tests usedwere as
follows: theLetter-Numbers andDigits tests of theWAIS
III (Wechsler, 1999) for attention/working memory; the
TMTPart A (Reitan&Davidson, 1974) and the Symbol
Digit Modalities Test (Smith, 2002) for information
processing speed; the California Verbal Learning Test–
Part II (Delis, Kramer, Kaplan,&Ober, 2000) for verbal
memory and learning; the TMT Part B (Reitan &
Davidson, 1974), the Stroop Test (Golden, 2001), the
Wisconsin Card Sorting Test (Heaton, Chelune, Talley,
Kay, & Curtiss, 1993), and the Tower of London test
(Culbertson & Zillmer, 2001) for executive functions;
the Controlled Oral Word Association Test (Benton,
Hamsher, & Sivan, 1994) and the Animals Test (Kertesz,
1982) for verbal fluency; and the Grooved Pegboard Test
(Reitan &Wolfson, 1985) for motor function. Of these,
three (the TMT Parts A and B and the Controlled Oral
Word Association Test) comprised the NEU Screen,
which consequently covered three domains: attention/
working memory, executive functions, and verbal flu-
ency. ½T1Table 1 shows the characteristics of theNEU Screen
(available at www.flsida.org/NEU). In both methods,
scores were adjusted for age, gender, and educational
level, according to the available local normative data.
Cognitive impairment was defined as performing at
least one standard deviation in standardized t scores
below the normative mean in at least two cognitive
domains in the comprehensive neuropsychological bat-
tery and at least one standard deviation in standardized t
scores below thenormativemean in at least one cognitive
domain in the NEU Screen.
Premorbid intelligence was evaluated by the Vocab-
ulary test of the WAIS III. Depressive symptoms were
evaluated by the Beck Depression Inventory II (Beck,
Steer, & Brown, 1996). Potentially confounding
comorbidities for cognitive impairmentwere recorded as
a clinical variable, based on international consensus in
the field, as was their degree of severity (Antinori et al.,
2007). Such comorbidities included current or previous
CNS-related disease, current or previous psychiatric
disorder, current use of psychopharmacological medi-
cation, use of illicit drugs, coinfection with hepatitis C
virus, and non2HIV-related neurologic condition.
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Data Analyses
The statistical characteristics of the NEU Screen were
compared for different age cutoffs, specifically less than
30 versus at least 30, less than 40 versus at least 40, less
than 50 versus at least 50, and less than 60 versus at least
60 years old. Sensitivity, specificity, and negative and
positive predictive values (PPV and NPV) were calcu-
lated relative to the gold standard as obtained by the
comprehensive neuropsychological assessment. The
percentage of correct classification was also calculated,
with 95%confidence intervals offered for all age cutoffs.
Variables associated with cognitive impairment were
described and descriptive statistics, t tests, and ANOVAAQ:3
tests were used for data analyses. All comparisons were
univariate and two-tailed, and statistical significance
was set at p , .05. All analyses were performed using
SPSS Statistics v15 (SPSS Inc., Chicago, IL).
Results
Characteristics of the Sample
Participants were mostly men (80%), who had acquired
infection via men having sex with men (51%) and had
a median (interquartile range) age of 43 (37; 48) years
and 11 (9; 15) years of education.Most of themwere on
antiretroviral treatment (77%) and presented an un-
detectable plasma viral load (70%) with a median cur-
rent CD41 T-cell count of 511 (375; 720) cells/mL and
a median nadir CD41 T-cell count of 223 (101; 360)
cells/mL. A total of 18 (5%) individuals presented po-
tentially confounding comorbidities for cognitive im-
pairment. The remaining demographic and clinical
characteristics are displayed in½T2 Table 2.
Cognitive impairment was present in 188 (51%)
participants, according to the comprehensive neuro-
psychological battery, and was associated with fewer
years of education (p5 .004), lower nadir CD41 T-cell
count (p 5 .003), lower premorbid intellectual level
(p , .001), presence of comorbidities for cognitive
impairment (p 5 .001), and the severity of those
comorbidities (p 5 .001).
Comparison of Age-Based Cutoff Points
Some of the comparisons found demographic and clin-
ical variables to be unequally distributed among groups.
Themost important factor revealedwas the nadirCD41
T-cell count, which was unbalanced across all the sub-
groups. The cutoff that showed the greatest difference
was 40 years, with people aged 40 or older showing
more years since HIV diagnosis (p , .001), fewer years
of education (p 5 .009), a greater presence of cognitive
complaints (p5 .046),more instances of anundetectable
viral load (p , .001), and a lower nadir CD41 T-cell
count (p , .001). The comparison that indicated least
unbalance was the 60-year cutoff, with people aged
60 or older showing lower nadir CD41 T-cell counts
(p 5 .031). Of note, comorbidities were distributed
uniformly across all the age subgroups.
With regard to the accuracy of the NEU Screen, sensi-
tivity became higher as age increased, except for the
50-year cutoff. The same effect occurred for specificity,
with the exception of the 30-year cutoff. The lowest val-
ues detectedwere in the subgroup of people younger than
30 years (,30 vs.$ 30): sensitivity 69.3%versus 75.4%;
specificity 65.0% versus 73.7%; PPV 56.2% versus
75.8%;NPV76.4%versus73.2%.Thegreatest accuracy
was revealed in the subgroup of people aged 60 or older
(,60 vs. $ 60): sensitivity 74.0% versus 90.9%; speci-
ficity 71.2% versus 92.3%; PPV 73.1% versus 90.9%;
NPV 72.1% versus 92.3%. The correct classifications at
that cutoff were 72.6% versus 91.6%, respectively.
½T3Table 3 shows the results for all the age subgroups.
Discussion
The goal of the present investigation was to determine
the diagnostic accuracy of the NEU Screen for detecting
Table 1. Characteristics of the NEU Screen
Cognitive Domain Test Score Approximate Duration, minutes
Information processing speed TMT-A Total time 2
Executive functioning TMT-B Total time 3
Verbal fluency COWAT Total score 5
Adapted from J.A. Mun˜oz-Moreno, et al. (2013). A brief and feasible paper-based method to screen for cognitive impairment in HIV-
infected patients: the NEU Screen. , JAIDS, 63(5), 589. The NEU Screen is available at www.flsida.org/NEU.
Note. COWAT 5 Controlled Oral Word Association Test; TMT-A 5 Trail Making Test-Part A; TMT-B 5 Trail Making Test-Part B.
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cognitive impairment in PLWH at different ages. To
make our study samplemore representative,we included
PLWH with diverse clinical conditions. Consequently,
a high rate (51%) of cognitive impairment was detected.
A considerable percentage of participants in the sample
were not receiving antiretroviral treatment (23%), were
not virally suppressed (30%), and presented a potential
confounding comorbidity for cognitive impairment
(5%), all circumstances that could be related to this high
frequency of cognitive disruption. Nonetheless, this rate
of impairment was similar to that seen in other studies
that have included PLWH with comorbidities and di-
verse clinical conditions (Bonet et al., 2013; Heaton
et al., 2010). The variables related to cognitive impair-
ment that we foundweremostly the same as those found
traditionally in the field: low premorbid intellectual
level, few years of education, presence of comorbidities,
severity of those comorbidities, and low nadir CD41 T-
cell count (Heaton et al., 2010; Morgan et al., 2012;
Muñoz-Moreno et al., 2014; Patel et al., 2013).
The NEU Screen showed the greatest degree of di-
agnostic accuracy in adults aged 60 years or older with
HIV, with a sensitivity score of 91% and a specificity
Table 2. Demographic and Clinical Characteristics
of Study Participants
N5 368
Gender, n (%)
Male 295 (80)
Female 73 (20)
Age, years, median (IQR) 43 (37–49)
Infection route, n (%)
MSM 185 (50)
Heterosexual 72 (20)
Injecting drug user 62 (17)
Other 13 (3)
Unknown 36 (10)
Education, years, median (IQR) 11 (9–15)
Time since HIV diagnosis, years,
median (IQR)
10 (3–15)
On ART, n (%) 283 (77)
CD41 T-cell count, cells/mL, median
(IQR)
511 (375–720)
Nadir CD41 T-cell count, cells/mL,
median (IQR)
223 (101–360)
Undetectable viral load, n (%)a 251 (70)
Highest viral load, copies/ml,
median (IQR)
86,500
(17,000–226,500)
HCV coinfection, n (%)
Yes 70 (20)
No 263 (73)
Unknown 26 (7)
Premorbid intelligence, mean (SD)b 54 (8)
Depressive symptoms, mean (SD)c 11 (10)
Self-reported cognitive complaints,
n (%)
191 (52)
Cognitive impairment, n (%) 188 (51)
Comorbidities for cognitive
impairment, n (%)d
145 (39)
Severity of comorbidities, n (%)d
None 223 (61)
Table 2. (continued)
N 5 368
Contributing 127 (34)
Confounding 18 (5)
HAND, n (%)e
Asymptomatic neurocognitive
impairment
66 (45)
Mild neurocognitive disorder 80 (54)
HIV-associated dementia 1 (1)
Note. ART5 antiretroviral therapy; HAND 5 HIV-associated
neurocognitive disorder; HCV5 hepatitis C virus; IQR5
interquartile range; MSM5 men who had sex with men;
SD 5 standard deviation.
a Detection limit of 50 copies/ml.
b Assessed by the Wechsler Adult Intelligence Scale III Vocab-
ulary test (Wechsler, 1999). Standardized t score: mean 50;
SD 10.
c Assessed by the Beck Depression Inventory
II (Beck, Steer, & Brown, 1996). Raw score: range from 0 to 63;
$17 is a cutoff for major depression in people living with HIV in
the United States (Hobkirk et al., 2015).
d Based on the Frascati criteria (Antinori et al., 2007).
e From those participants with cognitive impairment and without
confounding comorbidities.
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score of 92%. These values are remarkable, given that
values over 90% for either sensitivity or specificity are
truly uncommon among screening tools for HIV-related
cognitive impairment. This may be of particular useful-
ness for health care providers who are caring for older
adults living with HIV, as is the case of nurses, because
they are in a key position to know which of their care
recipients are at risk of developing cognitive impairment.
It is important to note that our stratification into age
subgroups for purposes of comparison led to smaller-
sized groups, resulting in a diminished statistical power.
This was particularly important for the subgroup of
people aged 60 years or older (n5 24). Nonetheless, the
number of participants outside this group (i.e., younger
than 60)was higher as a result (n5 344), and the general
trend observed across all cutoffs was mostly clear-cut,
detecting greater accuracy with increasing age for the
remaining age cutoffs overall. Another effect of the
stratification by age cutoffs was the unequal distribution
among groups of some clinical variables that have been
related to cognitive disorders in PLWH. This may have
affected in some way the results observed.
Of previous studies, the Montreal Cognitive Assess-
ment instrument test has been assessed in terms of its
accuracy in detecting impairment in people older than60
years with HIV, with results showing a sensitivity of
72%and specificity of 67% (Milanini et al., 2014). Both
valueswere lower than those claimed for theNEUScreen
when it was first described, namely 74% and 81%, re-
spectively (Muñoz-Moreno et al., 2013). And, as we
have seen here, when applied specifically to older
people with HIV, the NEU Screen yields significantly
higher accuracy scores, 91% and 92%, respectively.
Nevertheless, these results can only be
AQ:1
generalized to
similar populations. In this regard, our study sample
considered variable clinical conditions, comprising in
particular people on and off treatment, as well as people
with potential confounding comorbidities. Although we
have attempted to take into account these and other
potentially relevant variables in our data analyses, they
may have had an impact on our results that we did not
control for.
Conclusion
This is one of the first studies investigating the properties
of a screening method for cognitive impairment in an
aging HIV population. Some fairly optimal character-
istics are revealed, suggesting that theNEUScreen canbe
of great utility in the clinical context as a screening tool
for detecting cognitive dysfunction in HIV populations.
Nurses and other qualified professionals can play an
important role in this regard because they are in a good
position to detect cognitive changes in adults aging with
HIV. This will help them detect potential impairments,
as well as be ready for possible interventions. Our find-
ings are also of particular relevance because the HIV
population as a whole is aging. In a few years, most
people with HIV will be older than 50 years, and age-
related morbidities will appear in this population com-
plementarily to the long-term effects of HIV. Such
comorbidities can include a wide range of potential
malignancies, including oncologic, metabolic, and bone
complications, and also brain disorders. The availability
of a practical and reliable screening method such as the
NEU Screen to detect at an early stage the presence of
Table 3. Accuracy of the NEU Screen According to the Different Age Cutoffs
Age Subgroup Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) Correct Classification
,30 years (n5 33) 69.3 (38.8–89.6) 65.0 (40.9–83.6) 56.2 (30.5–79.2) 76.4 (49.7–92.1) 66.6
$30 years (n5 355) 75.4 (68.3–81.4) 73.7 (66.1–80.2) 75.8 (68.6–81,8) 73.2 (65.6–79.8) 74.6
,40 years (n5 129) 70.1 (57.5–80.4) 72.5 (59.5–82.7) 73.4 (60.6–83.3) 69.2 (56.4–79.7) 71.3
$40 years (n5 239) 77.6 (69.0–84.5) 72.8 (63.7–80.4) 74.6 (65.9–81.7) 76.1 (66.9–83.4) 75.3
,50 years (n5 289) 76.1 (68.3–82.5) 71.8 (63.5–78.8) 73.6 (65.8–80.3) 74.4 (66.1–81.3) 74.0
$50 years (n5 79) 70.7 (54.2–83.3) 76.3 (59.3–87.9) 76.3 (59.3–87.9) 70.7 (54.2–83.3) 73.4
,60 years (n5 344) 74.0 (66.7–80.1) 71.2 (63.6–77.8) 73.1 (65.9–79.3) 72.1 (64.5–78.6) 72.6
$60 years (n5 24) 90.9 (57.1–99.5) 92.3 (62.0–99.6) 90.9 (57.1–99.5) 92.3 (62.0–99.6) 91.6
Note. CI5 confidence interval; NPV5 negative predictive value; PPV5 positive predictive value. Values expressed as percentages
except when indicated.
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neurological decline in the aging HIV population thus
fulfills an urgent need in today’s clinical context.
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